CTKB

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 5.75 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cytek Biosciences Inc revenue for the last quarter amounts to 52.29M USD, increased 1.54 % YoY.

Cytek Biosciences Inc. EPS for the last quarter amounts to -0.04 USD, decreased -500.00 % YoY.

Cytek Biosciences Inc (CTKB) has 648 emplpoyees as of December 15 2025.

Today CTKB has the market capitalization of 621.42M USD.